Angiotensin Convertase Enzyme (ACE) inhibitors and Angiotensin receptor blockers (ARBs) have demonstrated a reduction in proteinuria and progression of DKD in well-established clinical trials of diabetic nephropathy [73,74,75,76,77]. Here, ACE is linked to diabetic kidney disease.